Citigroup
NVIV

Citigroup’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Citigroup’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-116
Closed -$1K – 6945
2022
Q1 		$1K Buy
+116
New +$1.1K ﹤0.01% 6266
2018
Q1 		– Hold
0
– – – 7792
2017
Q4 		– Hold
0
– – – 7740
2017
Q3 		– Hold
0
– – – 7220
2017
Q2 		– Hold
0
– – – 7290
2017
Q1 		– Sell
-2
Closed -$162K – 7045
2016
Q4 		$138K Buy
+2
New +$179K ﹤0.01% 5576
2016
Q3 		– Hold
0
– – – 6197
2016
Q2 		– Sell
-1
Closed -$118K – 6667
2016
Q1 		$188K Buy
+1
New +$107K ﹤0.01% 5151
2015
Q4 		– Sell
-2
Closed -$297K – 7145
2015
Q3 		$327K Buy
+2
New +$467K ﹤0.01% 4122
2015
Q2 		– Hold
0
– – – 6704

Other funds holding NVIV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citigroup's NVIV Position: Q2 2022 in Review

Citigroup sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q2 2022, closing a stake of 116 shares — an estimated $1K sold.

Citigroup first reported a position in NVIV in Q3 2015 and held it in 4 quarters. The position peaked at $327K in Q3 2015. 13 funds tracked by Wall St. Rank hold NVIV as of Q2 2022.

  • Citigroup reported no remaining InVivo Therapeutics Holdings Corp position as of Q2 2022 after selling out during the quarter.
  • Citigroup sold 116 InVivo Therapeutics Holdings Corp shares in Q2 2022, an estimated $1K.
  • Citigroup first reported a position in InVivo Therapeutics Holdings Corp in Q3 2015 and held it in 4 quarters.
  • Citigroup's InVivo Therapeutics Holdings Corp position peaked at $327K in Q3 2015.
  • 13 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q2 2022.

Based on Citigroup's 13F filing for Q2 2022, filed 10 Aug 2022.